Novo Nordisk announced that it will launch Wegovy in vial form, adding an injectable version of its flagship obesity drug to its product line. The new vial format will allow patients who prefer injections to use the same medication without the need for oral administration, expanding the company’s distribution options beyond the current injector pens.
The oral Wegovy pill began sales on January 5, 2026, and has shown promising early uptake in the United States. The vial launch is part of a broader strategy to broaden access for patients who may be reluctant to take a daily pill, while maintaining the drug’s strong market presence in the highly competitive GLP‑1 segment where Novo Nordisk holds a 62% volume share in 2025.
Financially, Novo Nordisk’s Q4 2025 earnings beat expectations, reporting earnings per share of $1.02 versus a forecast of $0.92 and revenue of $12.53 billion versus $11.99 billion. However, the company issued a bleak 2026 outlook, forecasting a sales and operating profit decline of 5% to 13% at constant exchange rates. Pricing pressures in the U.S., loss of exclusivity for the semaglutide molecule in some international markets, reduced Medicaid coverage, and transformation costs are cited as key headwinds. Gross margin contracted to 81% from 84.7% in 2024, reflecting the impact of these factors.
Management emphasized the strategic rationale behind the vial launch. CEO Mike Doustdar said the “painful impact of pricing pressure would be an investment for our future” and expressed encouragement over the early uptake of the Wegovy pill. CFO Karsten Knudsen highlighted that Novo delivered DKK 100 billion in net profit for 2025 and converted that into almost DKK 120 billion in cash from operations, describing the cash conversion as very strong.
Investors reacted negatively to the weak 2026 guidance, pricing headwinds, and margin compression, despite the new vial launch. The market’s focus on these headwinds underscores the importance of pricing strategy and margin management in the GLP‑1 market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.